Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting CD3L1-NRP2 disarms myeloid-driven tumor immune evasion

ABSTRACT: CD3 ligand 1 (CD3L1, ITPRIPL1), an emerging immune checkpoint, sustains immune privilege in testis and facilitates tumor immune evasion. Targeting CD3L1 with a monoclonal antibody demonstrates potent antitumor activity in preclinical models and spontaneous tumors in companion animals. In an ongoing clinical trial, anti-CD3L1 therapy unexpectedly activated tumor-associated macrophages (TAMs) within tumor microenvironment (TME), surpassing its anticipated role in T-cell reactivation. Mechanistic studies identified neuropilin-2 (NRP2) as the primary receptor on macrophages and uncovered the CD3L1-NRP2 axis as a critical driver of immunosuppressive M2 TAM polarization. Strikingly, in T-cell-deficient osteosarcoma models, anti-CD3L1 treatment reprogrammed TAMs toward an anti-tumor M1 phenotype, suppressing tumor progression. Clinical data corroborated these findings, revealing profound TME remodeling in advanced solid tumors. Our results elucidate a dual role for CD3L1 in immune evasion, mediated through both T-cell suppression and macrophage polarization, and highlight anti-CD3L1 as a multifaceted therapeutic strategy that enhances antigen presentation via TAM modulation.

ORGANISM(S): Mus musculus

PROVIDER: GSE304961 | GEO | 2026/05/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Exosomal FABP5 Drives HCC Progression via Macrophage Lipid 1 Metabolism and Immune Microenvironment Remodeling

Project description:Introduction: The progression of hepatocellular carcinoma (HCC) is intricately linked to complex interactions within the tumor microenvironment (TME), where the reprogramming of tumor-associated macrophages (TAMs) plays a pivotal role. However, how HCC cells regulate TAM metabolism and function via extracellular vesicles, such as exosomes, remains incompletely understood. Methods: We isolated exosomes from HCC cell lines and co-cultured them with macrophages. Using proteomics, lipid analysis, flow cytometry, and animal models, we evaluated the effects of exosomal FABP5 on macrophage polarization and lipid metabolism. The role of FABP5 in tumor progression was assessed via in vivo experiments. Results: This study reveals that HCC cells release fatty acid-binding protein 5 (FABP5) via exosomes, transferring it to TAMs, thereby inducing significant lipid metabolism reprogramming in macrophages. Mechanistically, exosomal FABP5 promotes lipid accumulation by activating the PPARγ signaling pathway, while potentially inhibiting the PPARα signaling pathway to reduce fatty acid oxidation, ultimately driving TAM polarization towards an M2 phenotype, characterized by increased secretion of immunosuppressive cytokines and a pro-tumor phenotype. Clinical data analysis indicates that high FABP5 expression in HCC tissues correlates with poor patient prognosis. In liver-specific FABP5 knockout mouse models and HCC xenograft models, FABP5 deletion significantly suppressed tumor growth, reduced M2-type TAM infiltration and lipid accumulation, and enhanced anti-tumor immune responses. Conclusion: These findings collectively uncover exosomal FABP5 as a key mediator of metabolic and immune communication between HCC and TAMs, promoting HCC progression by remodeling the tumor immune microenvironment, and suggest FABP5 as a potential therapeutic target for HCC.

2025-09-12 | PXD068213 | Pride

Macrophage-specific BCAT1 deficiency drives lipid-associated immunosuppressive remodeling and promotes HCC progression

Project description:<p>The heterogeneous and immunosuppressive tumor microenvironment (TME) remains one of the major factors to the poor immunotherapeutic response in hepatocellular carcinoma (HCC). Tumor-associated macrophages (TAMs) are central orchestrators of this suppressive niche, yet the metabolic programs regulating their pro-tumorigenic functions remain incompletely understood. Here, we identify branched-chain amino acid transaminase 1 (BCAT1) as a metabolic checkpoint in TAMs that constrains tumor progression. Deficiency of BCAT1 in TAMs induces metabolic reprogramming, elevating intracellular crotonate levels and promoting histone crotonylation, which epigenetically activates lipid metabolism programs. This shift promotes TAM polarization toward a lipid-associated, immunosuppressive phenotype that accelerates HCC progression primarily by suppressing CD8+ T cell-mediated antitumor immunity</p>

2025-12-28 | MTBLS13579 | MetaboLights

Blocking CX3CR1+ Tumor-associated Macrophages Synergize with anti-PD-1 Therapy in Hepatocellular Carcinoma

Project description:The efficacy of immune checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC) treatment remains limited, warranting further investigation into the underlying mechanisms. Accumulating evidence indicates that myeloid cells within the tumor microenvironment (TME) play a role in immune evasion and treatment resistance. In this study, we aimed to explore the contribution of tumor-associated macrophages (TAMs) in the HCC TME. Our findings unveil the critical involvement of CX3C motif chemokine receptor 1 (CX3CR1)-positive TAMs in inducing T cell exhaustion through interleukin-27 (IL-27) secretion, providing valuable insights into the mechanisms underlying the suboptimal efficacy of anti-PD-1 therapy in HCC. Additionally, we identified prostaglandin E2 (PGE2) released by immune-attacked tumor cells as a key driver of CX3CR1+ TAM recruitment. To enhance the therapeutic response to current anti-PD-1 therapy, we propose a novel treatment strategy that combines targeted depletion of CX3CR1+ TAMs with anti-PD-1 therapy. Overall, our study contributes to the understanding of TAMs' role in cancer immunotherapy and presents potential clinical implications for HCC treatment. By targeting CX3CR1+ TAMs in conjunction with anti-PD-1 therapy, we have the potential to enhance the effectiveness of immunotherapeutic interventions in HCC patients.

2024-07-25 | GSE263240 | GEO

Targeting Siglec-10/α3β1 Integrin Interactions Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer

Project description:Tumor-associated macrophages (TAMs) in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) exhibit immunosuppressive phenotypes and impaired phagocytic activity, facilitating tumor progression and immune evasion. Here, we identify integrin α3β1, composed of ITGA3 and ITGB1 subunits, as a sialylated glycoprotein ligand for Siglec-10, an inhibitory glyco-immune checkpoint receptor highly expressed on TAMs in PDAC. The interaction between Siglec-10 on TAMs and α3β1 on PDAC cells suppresses macrophage-mediated phagocytosis, thereby promoting immune evasion. Consistently, disrupting Siglec-10 interactions with monoclonal antibodies significantly enhances macrophage phagocytosis of PDAC cells and alleviates myeloid cell-mediated inhibition of T cell proliferation and activation in vitro. In both a PDAC xenograft mouse model engrafted with human macrophages and a human Siglec-10 transgenic mouse model, targeting Siglec-10 with monoclonal antibodies reduces PDAC tumor growth. These findings suggest that the Siglec-10 interactions are key mediators of TAM-driven immune evasion in PDAC and highlight the therapeutic potential of targeting these interactions to restore anti-tumor immunity in PDAC.

2025-09-16 | GSE303261 | GEO

Blockade of PF4-induced Th1-Treg polarization enhances anti-tumor immunity (Bulk RNA-Seq)

Project description:The tumor microenvironment (TME) contains various immune-suppressive cells such as T helper 1-polarized regulatory T cells (Th1-Tregs). However, little is known about the mechanism behind the abundant presence of Th1-Tregs in TME. In this work, we demonstrate that selective depletion of arginase I (Arg1)-expressing tumor associated macrophages (Arg1+ TAMs) inhibits tumor growth and concurrently reduces the Th1-Treg ratio in TME. Notably, Arg1+ TAMs secrete platelet factor 4 (PF4) that reinforces interferon-γ (IFN-γ)-induced Treg polarization into Th1-Tregs in a manner dependent on CXCR3 and the IFN-γ receptor. Both genetic PF4 inactivation and PF4 neutralization hinder Th1-Treg accumulation in TME, consequently suppressing tumor growth. Collectively, our study highlights the importance of Arg1+ TAM-produced PF4 for high Th1-Treg levels in TME to suppress anti-tumor immunity, and demonstrates PF4 neutralization as a potential cancer immunotherapeutic strategy.

2024-11-07 | GSE252052 | GEO

Blockade of PF4-induced Th1-Treg polarization enhances anti-tumor immunity

Project description:The tumor microenvironment (TME) contains various immune-suppressive cells such as regulatory T cells (Tregs) and M2-like tumor associated macrophages (TAMs) that express the enzyme arginase I (Arg1). T helper 1-polarized Treg (Th1-Treg) is a Treg subset that markedly accumulate in tumor tissues, suppressing anti-tumor immunity. However, little is known about the mechanism behind the abundant presence of Th1-Tregs in TME. Here we show that Arg1-expressing TAMs (Arg1+ TAMs) play critical roles for the high Th1-Treg ratio in TME. Selective depletion of Arg1+ TAMs using the VeDTR system inhibited tumor growth and concurrently reduced the Th1-Treg ratio in TME. Notably, Arg1+ TAMs secreted platelet factor 4 (PF4) that polarized Tregs to Th1-Tregs in a CXCR3-dependent manner. Both genetic PF4 inactivation and PF4 neutralization hindered Th1-Treg accumulation in TME, consequently suppressing tumor growth. Collectively, our study highlights the importance of M2-like TAM-produced PF4 for high Th1-Treg levels in TME to suppress anti-tumor immunity, and demonstrates PF4 neutralization as a potential cancer immunotherapeutic strategy by intervening the M2-like TAM/Th1-Treg axis.

2024-11-07 | GSE251735 | GEO

tRNA m1A modification enhances anti-tumor immunity in macrophages by promoting translation of key interferon associated genes [TAMs bulk RNA-seq]

Project description:Tumor-associated macrophages (TAMs) play a crucial role in tumor progression through their recruitment, polarization, and interaction with T cells in the tumor microenvironment (TME). However, the mechanisms underlying the post-transcriptional and translational regulation of TAMs in the TME remain largely unknown. In this study, we investigate the role of tRNA N1-methyladenosine (m1A) modification in controlling the behavior of macrophages in response to TME stimuli. We demonstrate that the m1A “writer” enzymes TRMT61A is highly enriched in the anti-tumoral and phagocytotic TAM subset, and TRMT61A is rapidly downregulated in macrophages upon stimulation with multiple TME components. Macrophage-specific knockout of TRMT61A leads to increased infiltration of TAMs, impaired CD8+ T cell function, and enhanced tumor growth. To further explore the biological effects of m1A deficient macrophages, we performed RNA sequencing analysis of TRMT61A-KO and WT TAMs derived from tumor bearing Trmt61af/fLysmCre and Trmt61af/f mice. The Gene ontology (GO) and Gene set enrichment analysis (GSEA) documented that the interferon response and the STAT1/IL-12 signaling pathway were impaired in TAMs upon TRMT61A deletion, indicating that TRMT61A is critical for macrophages to control interferon responses and exert anti-tumor effect in the TME.

2026-03-04 | GSE239606 | GEO

Complex interaction of tumor-derived factors instructs the niche specific phenotypes of tumor-associated macrophages (in vivo ATAC-Seq)

Project description:Despite the pivotal role of tumor-associated macrophages (TAMs) in modulating anti-tumor immunity, the conserved patterns and molecular determinates for the formation of diverse TAM subsets remain largely elusive. In this study, we uncovered the exclusive distribution of pro-angiogenic and MHC-II programs of TAMs are well-conserved, and identified key genes and pathways required for macrophage polarization by tumor cells by CRISPR screen. Notably, we demonstrated that multiple TAM phenotypes were mainly shaped by the synergistic and antagonistic interactions between GM-CSF, PGE2, and lactic acid. We further found the inactivation of Adar, an RNA-editing enzyme, reprograms TAMs into an ISG+ phenotype characterized by the high expression of immune stimulatory genes, thereby enhancing the anti-tumor immune response. Thus, our study illuminates the molecular principles underlying the generation and rewiring of TAM functional phenotypes.

2025-08-03 | GSE269029 | GEO

Complex interaction of tumor-derived factors instructs the niche specific phenotypes of tumor-associated macrophages (in vitro human macrophage RNA-Seq)

2025-08-03 | GSE301110 | GEO

Tumor-instructed glutamine synthesis in cancer-associated fibroblasts promotes pro-tumor macrophages

Project description:In the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs) play a crucial role in promoting tumor progression by creating an immunosuppressive environment through cytokine secretion and antigen presentation. While previous studies have demonstrated that CAFs exhibit distinct metabolic profiles compared to normal fibroblasts, it remains unclear how these metabolic programs influence the immune landscape within tumors and which factors drive metabolic reprogramming in CAFs. Here, we found that glutamine synthesis by CAFs promotes the polarization of pro-tumorigenic tumor-associated macrophages (TAMs), and supports tumor growth by altering TAM composition, highlighting the pivotal role of CAFs in shaping the immunosuppressive TME. Mechanistically, we found that tumor-derived palmitic acid activates a signaling cascade involving Toll-like receptor 4 (TLR4), Syk, and NF-κB in fibroblasts, leading to inflammatory CAF polarization, and IL-6-induced glutamine synthesis. These findings uncover a novel metabolic symbiosis whereby tumor cells manipulate TAM polarization through CAF-mediated glutamine metabolism, presenting potential therapeutic targets for cancer immunotherapy.

2025-05-26 | GSE297727 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data